Iverson featured on NPR's Morning Edition
September 25, 2008
Iverson was featured on NPR's Morning Edition in a piece entitled, "Tailoring Treatments To Patients Genetics". The piece focused on Biotech companies who are marketing products tailored specifically to the genetic makeup of individual patients in an effort to make dosages more precise and more effective. In the segment, Iverson CEO Dean Sproles talked about genetic testing and Warfarin. To listen to the full story, visit the following link:
www.npr.org back to top
DNA Direct and Iverson Genetics Announce Partnership to Provide Personalized Patient Reports for Warfarin Dosing Test Results
July 10, 2008 (Seattle, WA and San Francisco, CA)
DNA Direct, Inc. and Iverson Genetic Diagnostics, Inc. today announced that the companies will collaborate to offer personalized reports for individuals receiving Iverson's molecular-based assay for testing sensitivity to warfarin, a commonly used anticoagulant. DNA Direct will provide a customized, web-enabled tool for Iverson customers, allowing physicians who work with Iverson to offer their patients a personalized report that explains their test results in a patient-friendly, interactive format. For more information: http://www.smartbrief.com. back to top Iverson joins the Puget Sound Healthcare Alliance
February 21, 2008 (Seattle, WA)
The Puget Sound Health Alliance is a regional partnership involving employers, physicians, hospitals, patients, health plans, and others working together to improve quality and efficiency while reducing the rate of health care cost increases across King, Kitsap, Pierce, Snohomish and Thurston Counties.
Alliance participants agree to use evidence to identify and measure quality health care, then produce publicly-available reports designed to help improve health care decision-making. Reports measuring the quality of care provided in the Puget Sound region, along with useful information and tools, can be helpful in health care decisions, including identifying effective care, choosing or designing health benefit plans, deciding which doctor to see, knowing what questions to ask to get the best quality, and understanding what we each can do to improve our own health. For more information: http://www.pugetsoundhealthalliance.org . back to top Iverson attends the 19th annual Washington Physician Assistant Winter Conference in Seattle, WA January 26th-28th
January 30, 2008 (Seattle, WA)
Iverson Genetic Diagnostics, Inc. attends the 19th annual WAPA winter conference, held in Seattle , WA . The Washington Physician Assistant Association is the organizational voice of Physician Assistants in Washington State . WAPA maintains a close relationship with the Washington State Medical Association and effectively represents PA professionals to government agencies, health professionals, the general public, and AAPA.
For more information: http://www.wapa.com/
 
back to top
Thrombosis, Warfarin Dosing, Tamoxifen Response, Factor II, Factor V and MTHFR Assays Validated January 13, 2008 ( Seattle , WA )
Iverson Genetic Diagnostics has completed the first round of validation that will allow our products to be utilized by a medical provider. These tests will provide personalized information to patients via their clinician by direct analysis of their DNA. The Thrombosis Panel will allow a patient to determine their predisposition to forming blood clots that could cause heart attack and/or stroke. In regards to patients with a higher risk for developing pulmonary embolisms the Warfarin Dosing Panel will assist in the prediction of the optimal Warfarin (Coumadin) dose. Tamoxifen is the world's largest selling orally administered estrogen receptor modulator, which is used in the treatment of breast cancer. The Tamoxifen Response Panel will provide an analysis of the genetic variants involved with the metabolism and effectiveness of this medication. Factor II is a key enzyme in the coagulation cascade that strengthens blood clots. Factor V acts as an assembly site for the binding of Factor II which is important to prevent excess thrombosis. The MTHFR assay detects key variants in the metabolism of homocysteine which has been related to coronary artery disease, stroke, recurrent pregnancy loss, and genetic inherited thrombophilia.
back to top Iverson Genetic Diagnostics Announces the Successful Completion of Series A Financing January 13, 2008 (Seattle, WA) The next round of financing will propel Iverson to advance research, product development, production, permits, licensing and other overhead costs. Key milestones to achieve during this phase of financing will include the development and product offering of our new recently acquired microarray synthesizer. The capability to custom design probe sequences on an array will allow a medical provider with the necessary tools to screen patients for genetic mutations which are important to their practice. Iverson Genetics will first offer pre-fabricated panel microarrays that will be able to detect the route cause for Upper Respiratory Tract Infections and specific strains of the Influenza virus that may or may not be treatable with the current medication. back to top
|
